Arcellx, Inc.
Arcellx, Inc. (ACLX): 5 pipeline candidates · ~23 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
22.5 months
D/E 0.50 · 0% dilution
Lead: Phase 1
5 candidates
N/A
0 buys · 11 sells (180d)
A transparent, data-derived signal for Arcellx, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.7B
Cash
$82.9M
Quarterly Burn
$58.2M
Runway
22.5 mo
Revenue
$1.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ACLX-001 | Phase 1 |
| ACLX-002 | Phase 1 |
| ACLX-004 | Preclinical |
| anito-cel | Phase 1 |
| Standard Lymphodepletion regimen | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
240
Total value held
$6.47B
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 6,720,803 | $771.7M |
| paradigm biocapital advisors lp | 5,774,016 | $663.0M |
| vanguard capital management llc | 4,850,436 | $556.9M |
| blackrock, inc. | 3,945,238 | $453.0M |
| nea management company, llc | 3,045,262 | $349.7M |
| pentwater capital management lp | 2,870,000 | $329.5M |
| vanguard portfolio management llc | 2,424,818 | $278.4M |
| sr one capital management, lp | 2,346,630 | $269.4M |
| fil ltd | 2,339,192 | $268.6M |
| hbk investments l p | 2,278,517 | $261.6M |
Showing top 10 of 240 institutional holders of Arcellx, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Arcellx, Inc.'s pipeline?
Arcellx, Inc. (ACLX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Arcellx, Inc.'s lead drug candidate?
Arcellx, Inc.'s most advanced tracked candidate is ACLX-001 (Phase 1) for Relapsed or refractory multiple myeloma (rrMM).
What is Arcellx, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Arcellx, Inc. has approximately 22.5 months of cash runway.
What is Arcellx, Inc.'s market capitalization?
Arcellx, Inc.'s market capitalization is approximately $6.7B.
Who is the CEO of Arcellx, Inc.?
Mr. Rami Elghandour is the chief executive officer of Arcellx, Inc. (ACLX).
Get the full picture on Arcellx, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.